{"name": "VistaGen Therapeutics",
 "permalink": "vistagen-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/vistagen-therapeutics",
 "homepage_url": "http://www.vistagen.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "vistagen",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2013,
 "founded_month": 4,
 "founded_day": 16,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "investor.relations@vistagen.com",
 "phone_number": "650-244-9990",
 "description": "Pluripotent stem cell technology ",
 "created_at": "Mon Jun 15 05:46:45 UTC 2009",
 "updated_at": "Tue Apr 16 10:57:41 UTC 2013",
 "overview": "\u003Cp\u003EVistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen\u2019s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube\u2122, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.\u003C/p\u003E\n\n\u003Cp\u003EVistaGen\u2019s small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       67],
      "assets/images/resized/0004/8533/48533v1-max-150x150.jpg"],
     [[200,
       90],
      "assets/images/resized/0004/8533/48533v1-max-250x250.jpg"],
     [[200,
       90],
      "assets/images/resized/0004/8533/48533v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO and Director",
    "person":
     {"first_name": "H.",
      "last_name": "Ralph Snodgrass",
      "permalink": "h-ralph-snodgrass",
      "image": null}},
   {"is_past": false,
    "title": "Chief Financial Officer and Director",
    "person":
     {"first_name": "A.",
      "last_name": "Franklin Rice",
      "permalink": "a-franklin-rice",
      "image": null}},
   {"is_past": false,
    "title": "President and Director",
    "person":
     {"first_name": "Shawn",
      "last_name": "K. Singh",
      "permalink": "shawn-k-singh",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$40.8M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://venturebeat.com/2008/12/22/vistagen-gobbles-up-1m-for-stem-cell-research/",
    "source_description": "VistaGen gobbles up $1M for stem-cell research",
    "raised_amount": 1000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 12,
    "funded_day": 22,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "California Institute for Regenerative Medicine",
         "permalink": "california-institute-for-regenerative-medicine",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0004/8573/48573v1-max-150x150.jpg"],
             [[250,
               83],
              "assets/images/resized/0004/8573/48573v1-max-250x250.jpg"],
             [[399,
               134],
              "assets/images/resized/0004/8573/48573v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://deals.venturebeat.com/2007/08/10/vistagen-raises-375m-for-stem-cell-derived-drugs/",
    "source_description": "VistaGen raises $3.75M for stem-cell derived drugs",
    "raised_amount": 3750000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 8,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Montaur Capital Partners",
         "permalink": "montaur-capital-partners",
         "image": null},
       "person": null}]},
   {"round_code": "post_ipo_equity",
    "source_url": "http://www.vistagen.com/?p=1105",
    "source_description": "VistaGen Announces $36 Million Strategic Financing Agreement",
    "raised_amount": 36000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 4,
    "funded_day": 10,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "384 Oyster Point Blvd., Suite #8",
    "address2": "",
    "zip_code": "94080",
    "city": "South San Francisco",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": 37.6656476,
    "longitude": -122.3843489}],
 "milestones":
  [{"description": "VistaGen Therapeutics and Duke University Enter Into Strategic Research Collaboration",
    "stoned_year": 2012,
    "stoned_month": 3,
    "stoned_day": 5,
    "source_url": "http://www.vistagen.com/?p=816",
    "source_text": null,
    "source_description": "VistaGen Press Release",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "VistaGen Therapeutics",
      "permalink": "vistagen-therapeutics"}},
   {"description": "VistaGen Therapeutics Enters Strategic Drug Screening Collaboration with Vala Sciences",
    "stoned_year": 2012,
    "stoned_month": 3,
    "stoned_day": 21,
    "source_url": "http://www.vistagen.com/?p=836",
    "source_text": null,
    "source_description": "VistaGen Press Release",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "VistaGen Therapeutics",
      "permalink": "vistagen-therapeutics"}},
   {"description": "VistaGen Licenses Breakthrough Stem Cell Culture Technology ",
    "stoned_year": 2012,
    "stoned_month": 4,
    "stoned_day": 16,
    "source_url": "http://www.vistagen.com/?p=851",
    "source_text": null,
    "source_description": "VistaGen Press Release",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "VistaGen Therapeutics",
      "permalink": "vistagen-therapeutics"}},
   {"description": "VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity",
    "stoned_year": 2012,
    "stoned_month": 4,
    "stoned_day": 25,
    "source_url": "http://www.vistagen.com/?p=862",
    "source_text": null,
    "source_description": "VistaGen Press Release",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "VistaGen Therapeutics",
      "permalink": "vistagen-therapeutics"}},
   {"description": "VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring",
    "stoned_year": 2012,
    "stoned_month": 10,
    "stoned_day": 16,
    "source_url": "http://www.vistagen.com/?p=914",
    "source_text": null,
    "source_description": "VistaGen Press Release",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "VistaGen Therapeutics",
      "permalink": "vistagen-therapeutics"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "OTC:VSTA"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        101],
       "assets/images/resized/0004/8535/48535v1-max-150x150.jpg"],
      [[250,
        168],
       "assets/images/resized/0004/8535/48535v1-max-250x250.jpg"],
      [[450,
        303],
       "assets/images/resized/0004/8535/48535v1-max-450x450.jpg"]],
    "attribution": null},
   {"available_sizes":
     [[[128,
        150],
       "assets/images/resized/0021/5799/215799v2-max-150x150.jpg"],
      [[213,
        250],
       "assets/images/resized/0021/5799/215799v2-max-250x250.jpg"],
      [[384,
        450],
       "assets/images/resized/0021/5799/215799v2-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}